Literature DB >> 18991616

The utility of ADCC responses in HIV infection.

Amy Chung1, Erik Rollman, Susanne Johansson, Stephen J Kent, Ivan Stratov.   

Abstract

Simple antibodies or vector-induced T cell immunity are unable to provide broad immunity to HIV. Although broadly reactive neutralising antibodies are a goal of vaccination, this remains elusive. There is growing evidence that HIV-specific antibodies that mediate their activity via the Fc-receptor, such as antibody dependent cellular cytotoxicity (ADCC), have an important role in controlling HIV infection. Newer assays are being developed that enable HIV-specific ADCC responses to be finely mapped. In turn, this should allow a more definitive analysis of the effectiveness of HIV-specific ADCC antibodies. However, progressive dysfunction of effector cells that mediate ADCC responses, such as NK cells, combined with immune escape variants that emerge from effective ADCC responses, likely undermine the utility of ADCC responses during chronic HIV infection. Nonetheless the utility of ADCC responses in preventing HIV infection requires urgent consideration.

Entities:  

Mesh:

Year:  2008        PMID: 18991616     DOI: 10.2174/157016208786501472

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  30 in total

1.  A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.

Authors:  Diego A Vargas-Inchaustegui; Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure.

Authors:  Amy W Chung; Gamze Isitman; Marjon Navis; Marit Kramski; Rob J Center; Stephen J Kent; Ivan Stratov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

3.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

4.  High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

Authors:  Justin Pollara; Lydia Hart; Faraha Brewer; Joy Pickeral; Beverly Z Packard; James A Hoxie; Akira Komoriya; Christina Ochsenbauer; John C Kappes; Mario Roederer; Ying Huang; Kent J Weinhold; Georgia D Tomaras; Barton F Haynes; David C Montefiori; Guido Ferrari
Journal:  Cytometry A       Date:  2011-07-06       Impact factor: 4.355

5.  Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.

Authors:  Leia H Wren; Amy W Chung; Gamze Isitman; Anthony D Kelleher; Matthew S Parsons; Janaki Amin; David A Cooper; Ivan Stratov; Marjon Navis; Stephen J Kent
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

6.  Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Peng Xiao; Jun Zhao; L Jean Patterson; Egidio Brocca-Cofano; David Venzon; Pamela A Kozlowski; Rachmat Hidajat; Thorsten Demberg; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

7.  Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac₂₅₁ infection of macaques.

Authors:  Namal P M Liyanage; Shari N Gordon; Melvin N Doster; Poonam Pegu; Monica Vaccari; Nebiyu Shukur; Luca Schifanella; Cynthia A Pise-Masison; Danuta Lipinska; Kamil Grubczak; Marcin Moniuszko; Genoveffa Franchini
Journal:  Virology       Date:  2014-01-21       Impact factor: 3.616

8.  Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Thorsten Demberg; Ranajit Pal; Marjorie Robert-Guroff
Journal:  Immunology       Date:  2015-06       Impact factor: 7.397

9.  Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

Authors:  Izabela Bialuk; Stephen Whitney; Vibeke Andresen; Ruth H Florese; Janos Nacsa; Valentina Cecchinato; Valerio W Valeri; Jean-Michel Heraud; Shari Gordon; Robyn Washington Parks; David C Montefiori; David Venzon; Thorsten Demberg; Marjorie Robert- Guroff; Gary Landucci; Donald N Forthal; Genoveffa Franchini
Journal:  Vaccine       Date:  2011-10-27       Impact factor: 3.641

10.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.